SynapDx Corp. aims to use RNA sequencing to lower the age of diagnosis for autism spectrum disorder into early toddlerhood, which would improve the odds of success for behavioral therapy.

The company has raised more than $33 million to develop an RNA-based screening tool for early detection of autism spectrum disorder. The company is recruiting a large prospective trial of a gene expression signature it believes can predict the risk of developing ASD.